PR Newswire06.17.19
Ortho Regenerative Technologies Inc., an emerging orthopedic and sports medicine technology company, announced the nomination of Claude LeDuc as its new president and CEO in replacement of Dr. Brent Norton who is stepping down from his operational role to focus on other initiatives. Dr. Norton will remain on the Board of Directors of the company and support Leduc in his new role to ensure a smooth transition and beyond.
"I am pleased to announce that Claude LeDuc is joining our company," stated Steve Saviuk, Chairman of the Board of Directors of Ortho RTi. "LeDuc has an outstanding track record of accomplishment in growing private and publicly traded bio-pharma companies. He is taking the helm of Ortho RTi as the company is commencing preparation for its first human trial to test its lead biopolymer, Ortho-R, for the treatment of rotator cuff injuries. Under his leadership, we look to the future with excitement and confidence."
Steve Saviuk also commented; "The company wishes to thank Dr. Norton for his service and leadership as president and CEO, and we are happy to be able to count on his continued support and contribution as a Board member".
"I am excited to be joining the Ortho RTi team at this critical time in the development of its Ortho-R program," stated Claude LeDuc. "The potential to develop Ortho RTi's proprietary biopolymer as a revolutionary platform for the treatment of any type of soft-tissues injuries is at our reach. I look forward to building on the strong foundations at Ortho RTi and leading the company to maximize its future potential."
LeDuc has cumulated 32 years of senior executive, CEO, and COO experience with private and Fortune 500 medical device and bio-pharma companies. He has spent 22 years in the musculoskeletal market, having occupied senior positions with Genzyme, Biomatrix, Serono and BioSyntech. He has raised more than $50 million in public & private financings after taking BioSyntech public on the TSX-V exchange as its CEO in 2004. During his 5-year tenure as BioSyntech CEO, he has worked closely with Ecole Polytechnique who is an active partner in the development of Ortho-RTi's proprietary platform, and was directly involved in the clinical and regulatory development of the BST-CarGel product which was later acquired by Orthopaedic giant, Smith & Nephew.
"I am pleased to announce that Claude LeDuc is joining our company," stated Steve Saviuk, Chairman of the Board of Directors of Ortho RTi. "LeDuc has an outstanding track record of accomplishment in growing private and publicly traded bio-pharma companies. He is taking the helm of Ortho RTi as the company is commencing preparation for its first human trial to test its lead biopolymer, Ortho-R, for the treatment of rotator cuff injuries. Under his leadership, we look to the future with excitement and confidence."
Steve Saviuk also commented; "The company wishes to thank Dr. Norton for his service and leadership as president and CEO, and we are happy to be able to count on his continued support and contribution as a Board member".
"I am excited to be joining the Ortho RTi team at this critical time in the development of its Ortho-R program," stated Claude LeDuc. "The potential to develop Ortho RTi's proprietary biopolymer as a revolutionary platform for the treatment of any type of soft-tissues injuries is at our reach. I look forward to building on the strong foundations at Ortho RTi and leading the company to maximize its future potential."
LeDuc has cumulated 32 years of senior executive, CEO, and COO experience with private and Fortune 500 medical device and bio-pharma companies. He has spent 22 years in the musculoskeletal market, having occupied senior positions with Genzyme, Biomatrix, Serono and BioSyntech. He has raised more than $50 million in public & private financings after taking BioSyntech public on the TSX-V exchange as its CEO in 2004. During his 5-year tenure as BioSyntech CEO, he has worked closely with Ecole Polytechnique who is an active partner in the development of Ortho-RTi's proprietary platform, and was directly involved in the clinical and regulatory development of the BST-CarGel product which was later acquired by Orthopaedic giant, Smith & Nephew.